Abstract
Respiratory Syncytial Virus (RSV) is a leading cause of serious lung infections in infants and young children, especially during the winter months. For decades, preventative options were limited, costly, or only available to babies at high-risk. The FDA approved Enflonsia (clesrovimab-cfor) in June 2025, given as a single injection to protect infants thorough their first RSV season. Since it is designed for broader infant use and can be distributed through programs such as Vaccines for Children, Enflonsia may help close long-standing gaps in RSV prevention.
Recommended Citation
Ghattas K, Smith R, Rawa A. Enflonsia (clesrovimab-cfor): A New Era in RSV Protection for Infants. Transformative Medicine. 2025; 4(3). doi: https://doi.org/10.54299/tmed/jzwe7522.
Included in
Community Health and Preventive Medicine Commons, Other Pharmacy and Pharmaceutical Sciences Commons